



GLAND PHARMA LIMITED

August 24, 2023

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Conclusion of US FDA Inspection at Dundigal Facility, Hyderabad
Ref: Our letter dated July 14, 2023

Further to our intimation dated July 14, 2023; this is to inform you that following the 'Good Manufacturing Practice (GMP) Inspection' by US FDA at the Company's Dundigal Facility at Hyderabad between 03rd July, 2023 and 14th July, 2023; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

Request to take the above information on record.

Yours truly,

For Gland Pharma Limited

P Sampath Kumar
Company Secretary and Compliance Officer

Regd. Office:

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India
Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office:

Plot No. 11 & 84, TSIIIC Phase: IV
Pashamylaram (V), Patancheru (M), Sangareddy District
Hyderabad 502307, Telangana, India
Tel: +91-8455-699999